Federica Guffanti
Mario Negri Institute for Pharmacological Research(IT)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, DNA Repair Mechanisms, Cancer Genomics and Diagnostics, Cancer-related Molecular Pathways
Most-Cited Works
- → Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations(2014)132 cited
- → Present and Future Perspective on PLK1 Inhibition in Cancer Treatment(2022)110 cited
- → Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer(2021)99 cited
- → Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma(2014)62 cited
- → VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status(2021)58 cited
- → Role and therapeutic potential of CDK12 in human cancers(2016)53 cited
- → LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors(2019)47 cited
- → Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts(2021)39 cited
- → In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models(2016)35 cited
- → Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy(2016)29 cited